Merck & Co., Inc. (MRK)

Merck's stock price has fluctuated, with a share price of $87.49 as of October 24, 2025, a 16.06% decrease from October 28, 2024. Key events include Q2 2025 earnings exceeding estimates, a quarterly dividend announcement of $0.81 per share, positive Phase 3 trial results for Keytruda, new product launches like Winrevair and Capvaxive, and the looming patent expiration of Keytruda's intravenous formulation. Institutional investors have adjusted their holdings, with some decreasing and others increasing their positions.

Merck experiences some demand seasonality, particularly for its vaccine portfolio, with a historically strong period between April and June. The diversified product portfolio helps mitigate extreme seasonality across the entire business, as the consistent need for oncology treatments and animal health products provides a more stable demand base.

Merck & Co., Inc. is a global biopharmaceutical company involved in discovering, developing, manufacturing, and marketing health solutions, primarily in pharmaceuticals and biotechnology. Key products include Keytruda (oncology), Gardasil (vaccines), and various treatments for infectious diseases, cardio-metabolic disorders, immunology, neuroscience, diabetes, hospital acute care, and animal health.

Merck operates globally, supplying products to various institutions worldwide and maintaining a strong presence in developed and emerging economies. It has manufacturing facilities in North America, South America, Western Europe, Africa, and Asia, with headquarters in Rahway, New Jersey. Recent expansions include a $3 billion facility in Elkton, Virginia, and a $57 million investment in Wilson, North Carolina.

Merck's brand reputation has been influenced by its focus on scientific innovation and performance in oncology and vaccines. Positive developments include the success of Keytruda and new product launches. Challenges include declining Gardasil sales in China and looming patent expirations, particularly for Keytruda. Potential headwinds include tariffs and evolving healthcare policies.

Merck & Co., Inc. is primarily owned by institutional investors, holding approximately 78% to 80% of the company's shares. Major institutional owners include Vanguard Group Inc and BlackRock, Inc. Individual insider ownership is less than 1%, while retail investors hold approximately 21.43% of the stock.